Company profile: Anthera
1.1 - Company Overview
Company description
- Provider of products to treat diseases associated with inflammation and autoimmune diseases, including Vernis Soin, a nail polish that also acts as a treatment formulated with essential oils of lavender, tea tree, and geranium to nourish, fortify, and protect nails.
Products and services
- Autoimmune Disease Therapeutics Development: Develops products to treat diseases associated with autoimmune diseases, focusing development on therapeutics for immune-related conditions, therapeutic-focused initiative aligned with Anthera Pharmaceuticals’ mission
- Inflammation Therapeutics Development: Develops products to treat diseases associated with inflammation, targeting treatment development for inflammation-related disorders, inflammation-focused program advances Anthera Pharmaceuticals’ core development activities
- Vernis Soin: Engineers essential-oil-infused nail polish with lavender, tea tree, and geranium oils to nourish, fortify, and protect nails, acting simultaneously as treatment and polish
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Anthera
HemoShear
HQ: United States
Website
- Description: Provider of the REVEAL-Tx platform, a drug discovery system combining biological and computational models to accelerate development of treatments for rare disorders. Offerings include HST5040, a clinical candidate for Propionic Acidemia and Methylmalonic Acidemia, and a human tissue-based model of rare liver disease developed in collaboration with Takeda.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HemoShear company profile →
BioMarin
HQ: United States
Website
- Description: Provider of innovative biopharmaceuticals for serious diseases and medical conditions, developing and commercializing them.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioMarin company profile →
Aspreva Pharmaceuticals
HQ: Canada
Website
- Description: Provider of pharmaceutical solutions focused on identifying, developing and commercializing new indications for approved drugs and drug candidates for underserved patient populations. Headquartered in Victoria, British Columbia, the company uses a collaboration strategy termed 'indication partnering'.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aspreva Pharmaceuticals company profile →
Cosciens Bio
HQ: United States
Website
- Description: Provider of biopharmaceutical diagnostic products, including Macimorelin, an orally active small molecule to diagnose adult growth hormone deficiency (AGHD), approved by the U.S. FDA and European Commission, and Macimorelin for childhood-onset growth hormone deficiency (CGHD) under development, leveraging its safety profile and clinical success in AGHD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cosciens Bio company profile →
Amolyt Pharma
HQ: France
Website
- Description: Provider of peptide-based therapeutics for rare endocrine and metabolic disorders, including Eneboparatide in development for hypoparathyroidism to produce sustained, stable blood calcium; AZP-3813, a peptide growth hormone receptor antagonist in development for acromegaly to suppress IGF1; AZP-40XX monoclonal antibodies targeting PTHR1 in preclinical evaluation for PHPT and HHM; and AZP-3404 that may restore fat and glucose metabolism.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amolyt Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Anthera
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Anthera
2.2 - Growth funds investing in similar companies to Anthera
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Anthera
4.2 - Public trading comparable groups for Anthera
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →